The expression of epidermal growth factor receptor (eGFr) is regulated by microrna (mirna)-128-b in non-small cell lung cancer (nSclc); however, the association between mirna-128-b expression and eGFr expression has not been determined in vivo. The expression of mirna-128-b was detected by reverse transcription (rT)-quantitative polymerase chain reaction (Pcr); semi-quantitative rT-Pcr was used to detect eGFr mrna expression; immunostaining was used to detect eGFr protein expression. The results revealed that expression of mir28b in cancer tissues was decreased compared with normal tissues, and the expression of eGFr mrna in cancer tissues was increased compared with normal tissues. immunohistochemistry analysis revealed that the normal tissues did not express eGFr protein, and the positive expression rate of eGFr in cancer tissues was 60%. Furthermore, the relative expression levels of mirna-128-b were demonstrated to be correlated with eGFr mrna and protein expression levels. in addition, the results revealed that mirna-128-b regulated eGFr expression in nSclc cells. in conclusion, the results of the present study suggested that mirna-128-b may regulate the expression of eGFr in nSclc cells, and that optimizing targeted therapy is conducive to the development of novel therapeutic strategies for the treatment of patients with lung cancer.
Introduction
lung cancer is one of the primary causes of cancer mortality worldwide (1) . non-small cell lung cancer (nSclc) accounts for ~85% of lung cancer cases, of which 75% exhibit distant metastases at diagnosis (2, 3) . Since the introduction of numerous novel chemotherapy drugs, chemotherapy has been reported to significantly improve survival (4) however, chemotherapeutic toxicity has been detected in large numbers of patients (5) .
Monoclonal antibodies and small molecule receptor tyrosine kinase inhibitors (TKis) are two targeted drugs commonly used for treating patients with advanced nSclc (6) . Previous studies have revealed that epidermal growth factor receptor (eGFr)-TKis are an effective treatment strategy that has a beneficial effect on tumors with EGFR gene mutations (6, 7) . Furthermore, an increase in eGFr gene copy numbers has been demonstrated to be associated with improved survival prognosis for patients treated with TKi (8). in addition, 20-40% of patients with nSclc have concurrent mutations and gene amplification (9, 10) . Recent studies have also demonstrated that some TKi-effective patients have no significant EGFR genetic changes (11) . For TKIs, there are no clear patient selection criteria. in addition to mutation and genetic amplification, there may be other effects of targeted drug mechanisms (12) Micrornas (mirnas/mirs) are a class of mature small non-coding rnas, varying between 22 and 25 nucleotides in length, that regulate gene expression at the post-transcriptional level by promoting degradation of target mrnas or inhibition of protein synthesis (12, 13) . dysregulated mirna expression has been demonstrated to be associated with numerous tumor types, thus suggesting that certain mirnas can function as oncogenes or tumor suppressor genes (13) . eGFr may be a mirna128-b target gene, and it has been demonstrated that in nSclc cells there is loss of heterozygosity in mirna128-b, which is associated with EGFR-TKIs curative efficacy (14) . However, the effect of mirna-128-b on the regulation of eGFr expression in nSclc remains unclear.
The present study aimed to investigate mirna-128-b and eGFr expression levels in nSclc cancer tissue compared with adjacent normal tissue, and investigate the association between the two factors and clinicopathological factors in patients with nSclc, in order to determine the role of mirna-128-b expression in lung cancer and the regulation of eGFr expression.
Materials and methods
Clinical data. Between March and august 2014, tissue specimens (cancer tissue and normal adjacent tissue) were collected
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following surgical treatment of 42 patients with nSclc in Shandong Tumor Hospital (Jinan, china). Patients had not previously received any other preoperative radiotherapy and chemotherapy therapies. Following collection, tissue specimens were stored at -80˚C prior to subsequent analysis. The diagnosis and classification of these patients were performed by a professional pathologist, and later verified by subsequent morphological and immunohistochemistry analyses. Patients were staged according to the TnM system (15) . The present study was granted ethical approval by the Shandong Tumor Hospital ethics committee, and written informed consent was obtained from patients. according to the alterations in mirna-128-b expression in cancer tissues relative to normal tissues, tissue specimens were divided into the following three groups: The descending group, stable group and increasing group. The clinical data of patients included in the present study are presented in RNA extraction. Total rna extraction was performed using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, Ma, uSa), and isolated rna samples were then treated with dnase (2 u/µg; Promega corporation, Madison, Wi, uSa).
Reverse transcription (RT)-quantitative polymerase chain reaction (qPCR) analysis of miRNA-128-b. a mirVana
Quantitative rT-Pcr mirna kit (ambion; Thermo Fisher Scientific, Inc.) was used to perform RT (44˚C for 1 h and 92˚C for 10 min) according to the manufacturer's protocol. Briefly, total rna (200 ng) was added to specific rT primers to synthesize complementary (c)dna. The qPcr reaction consisted of the initial denaturation at 95˚C for 10 min, followed by 40 cycles for 15 sec at 95˚C and 1 min at 60˚C. The expression of miR128-b relative to RNA, U6 small nuclear 1 (rnu6B) was calculated using the 2 -ΔΔcq method (16) . all assays were performed in triplicate. Primer sequences were as follows: mirna-128-b, forward, 5'-cGc GcT cac aGT Gaa ccG-3, reverse, 5'-GTG caG GGT ccG aGG T-3'; and rnu6B, forward, 5'-cTc GcT TcG Gca Gca ca-3' and reverse, 5'-aac GcT Tca cGa aTT TGc GT-3'.
Semi-quantitative RT-PCR. rT was performed using ProtoScript ® cdna single-stranded synthesis kit (new england Biolabs, inc., ipswich, Ma, uSa), according to the manufacturer's protocol; PCR amplification was performed using Platinum Blue Pcr SuperMix reagent (invitrogen; Thermo Fisher Scientific, inc.). initial denaturation was performed at 94˚C for 2 min followed by 40 cycles of 94˚C for 20 sec and 56˚C for 55 sec; and a final extension step for 1 min at 72˚C. mRNA primer sequences used were as follows: EGFR forward, 5'-aTG cTc cca cca c-3' and reverse, 5'-ccc TTc Gca cTT cTT aca c-3'; and β-actin forward, 5'-aTG aTG aTa TcG ccG cGc T-3' and reverse, 5'-TGG GTc aTc TTc TcG cGG TT-3'. The amplified product was analyzed on a 1.25% agarose gel, and eGFr mrna expression was determined by grayscale scanning of the agarose gel containing ethidium bromide. expression levels were calculated relative to β-actin expression. Data were semi-quantified using lightcycler analysis software v1.50 (roche diagnostics, Mannheim, Germany). all experiments were performed in triplicate.
EGFR immunohistochemistry (IHC) analysis. iHc was performed to investigate the expression of eGFr protein.
After blocking the non-specific protein-binding sites with 20% goat serum (oriGene Technologies, inc., Beijing, china) for 20 min at room temperature, anti-eGFr antibody staining (1:1,000; cat. no. Pa1-1110; Zymed; Thermo Fisher Scientific, inc.) was performed on a549 cells that were fixed with 4% paraformaldehyde at room temperature for 15 min and tissue sections obtained from patients that were fixed with 4% paraformaldehyde at 4˚C (17) . Subsequently, they were incubated with a goat anti-rabbit immunoglobulin-horseradish peroxidase secondary antibody (1:200; cat. no. TA130023; OriGene Technologies, Inc.) at 37˚C for 30 min. Tissue sections were classified as follows: 0, <10% positive cells; 1, 10% positive cells; 2, 11-50% positive cells; 3, >50% positive cells. The number of positive cells per field of view (0-100%) and staining intensity (0, negative; 1 weak positive; 2, medium positive; 3, strong positive) of eGFr was determined (18) . images were captured using an iX71-SiF microscope (olympus corporation, Tokyo, Japan) at x200 magnification. Two independent observers blinded to tissue status determined staining intensities in cell cytoplasm. image-Pro Plus software (Media cybernetics, inc., rockville, Md, uSa) was used to quantify the mean densities of the expression intensities of eGFr, as previously described (18) . immunohistochemical positive staining in the cytoplasm was assessed, and two observers blinded to tissue status evaluated positive staining of each tissue core. An average of five images per tissue core was used for quantitative analysis.
Statistical analysis. all experiments were repeated three times and the data are presented as the mean ± standard deviation. Statistical significant differences were determined by one-way analysis of variance followed by Fisher's least significant difference post-hoc test. Qualitative data were correlated using the Pearson correlation. rates were compared using the χ 2 test. Statistical analysis was performed using SPSS 19.0 software (IBM Corp., Armonk, NY, USA). P<0.05 was considered to indicate a statistically significant difference. Association bet ween miRNA-128-b expression and clinical pathological factors. relative expression levels of miRNA128-b was revealed to be significantly associated with differences in eGFr mrna expression and eGFr protein expression. However, no significant differences in miRNA 128-b expression regarding differences in sex, age, pathological type, operation stage and degree of differentiation were determined (Table i) .
Results
EGFR mRNA expression in tissues. rT-Pcr was performed to detect eGFr mrna expression in the cancer tissues and normal tissues of 42 patients (Fig. 2) . The results revealed that eGFr mrna expression was enhanced in cancer tissue compared with normal tissue in 69% of patients (T:N≥1.0). The mean eGFr mrna expression was revealed to be EGFR protein expression in tissue. iHc staining of eGFr protein was performed in 30 of the 42 tissue samples. eGFr protein staining was revealed to be negative (Fig. 3a) or weakly positive (Fig. 3B ) in normal tissue samples, in which staining was limited to basal levels (<10% positive cells). EGFR protein expression in cancer tissues was revealed to be increased compared with normal tissue samples. When the number of positive cells was 10% (1), the sample was considered positive for eGFr protein expression; eGFr positive expression was detected in 18 (60%) cancer tissues (Fig. 3c ). When the number of positive cells was >10% (2 and 3), the sample was considered to have high eGFr protein expression; eGFr protein was highly expressed in 10 patients ( Fig. 3d and e ). as demonstrated in Fig. 4 , eGFr protein expression was associated with TNM stage (P<0.05 TNM stage II or III vs. TNM stage i).
Association between the expression of miRNA-128-b and the expression of EGFR in lung cancer tissues.
Pearson correlation analysis demonstrated that there were significant negative correlations between the relative expression of mirna128-b and both eGFr mrna relative expression and eGFr protein expression (r=-0.69, P=0.02, Fig. 5a ; r=-0.43, P=0.02, Fig. 5B ). Fig. 6A and B ). In addition, Fig. 7 presented the results of immunohistochemistry analysis following transfection with mirna-128-b mimics or inhibitors. The expression of eGFr protein in cells treated with miRNA-128-b inhibitors was significantly upregulated compared with control cells; whereas eGFr protein expression was significantly downregulated in cells treated with mirna-128-b mimics compared with control cells (P<0.05 vs. control; Fig. 7B ).
miRNA-128-b regulates EGFR expression in lung cancer

Discussion
over the past 40 years, the understanding of potential cellular or genetic changes associated with lung cancer has developed. The eGFr signal transduction pathway has been suggested to represent a therapeutic target, leading to the development of small-molecule TKis. it has been reported that eGFr-TKis are only effective in 10-30% of patients with chemotherapy-refractory NSCLC (19) (20) (21) , and so the identification of novel regulatory molecules may optimize targeting therapy for lung cancer. mirnas are a class of small molecule non-coding rnas, and a considerable number of micrornas are located in tumor-associated gene loci or fragile sites, thus suggesting that mirnas may be involved in tumorigenesis. The deletion of chromosome 3p allele is common in the early stages of lung cancer, which results in dysregulation of eGFr expression (18) . mirna-128-b is located on chromosome 3p22, and regulates eGFr expression in nSclc cells via binding with the 3' untranslated region (3'uTr) (18) .
To the best of our knowledge, the association between mirna-128-b expression and eGFr expression has not been reported in nSclc, the previous study conducted a systematic (10) . eGFr may be a mirna-128-b target gene, and it has been demonstrated that in nSclc cells there is loss of heterozygosity in mirna-128-b, which is associated with eGFr-TKis curative efficacy (20, 21) . Firstly, differences in mirna-128-b expression and eGFr expression between cancerous tissue and normal tissue were compared. mirna-128-b expression was occasionally not detected in tumor tissues and was revealed to be decreased in cancerous tissue compared with normal tissue. The results demonstrated that eGFr mrna was expressed in all samples; however, the expression of eGFr mrna was revealed to be enhanced in cancerous tissue compared with normal tissue. The difference of the same mrna expression between normal tissues and cancerous tissues may be a result of the heterogeneity of the expression patterns in different tissue types or due to the biological behavior of the tumor. iHc results demonstrated that the expression of eGFr in normal tissues was negative or weakly positive, whereas the expression of eGFr protein in cancerous tissues was increased compared with normal tissues. consistent with a previous study (22) , expression levels of eGFr protein were revealed to be increased in stage iii nSclc compared with earlier stages of nSclc. it has been previously suggested that eGFr expression increases progressively in a stage-dependent manner in nSclc (23) . in addition, the correlation between mirna128-b expression and eGFr expression was analyzed in cancerous tissues. Pearson correlation analysis demonstrated that there were significant negative correlations between the relative mirna128-b expression and relative eGFr mrna and protein expression Previous studies have investigated the association between mirna expression and mrna expression in nSclc tissues. Tumor suppressor candidate 2 (TuSc2) is a tumor suppressor gene and is located on chromosome 3p21. mirna-93 and mirna-197 bind to the TuSc2 3'uTr to negatively regulate its expression in nSclc tissues (24). The results of the present study demonstrated that the relative expression of mirna-128-b was negatively correlated with the relative expression of eGFr mrna in cancerous tissue. in addition, the results revealed that mirna-128-b expression was sometimes absent in the tumor compared with the normal tissue, and the relative expression of mirna-128-b was decreased, unchanged and increased in three cases in cancer tissues, and was significantly correlated with EGFR protein expression.
Furthermore, the results of the present study suggested that mirna-128-b regulates eGFr expression in nSclc cells. a549 cells expressing eGFr and mirna-128-b were investigated, and eGFr expression was revealed to be downregulated following transfection with mimics, whereas eGFr expression was upregulated following treatment with inhibitors, and drug sensitivity was subsequently increased. Similarly, H157 cells are eGFr-expressing cell lines, and a previous study revealed that treatment with mirna-128-b inhibitors upregulated eGFr protein expression, while eGFr protein expression was downregulated following mirna-128-b mimic treatment (18) .
The results of present study suggested that mirna-128-b expression and eGFr expression were differentially expressed in cancer tissues compared with normal tissues, and the relative expression of mirna-128-b was negatively correlated with eGFr mrna and eGFr protein expression levels in cancerous tissues. mirna-128-b regulated eGFr expression in nSclc cells, thereby affecting the drug sensitivity of cells. These results suggested that mirna-128-b may exhibit an inhibitory role in lung cancer. However, the efficacy of existing anti-eGFr drugs for the treatment of lung cancer is limited, and thus the development of novel therapeutic strategies is necessary to successfully suppress signal transduction and eGFr expression. inhibition of signal transduction via eGFr-TKis and inhibition of eGFr expression via mirna-128-b may represent a novel therapeutic strategy for the treatment of patients with eGFr mutant-harboring nSclc.
